Expression levels of protein kinase C-alpha in non-small-cell lung cancer.

abstract：:Two cases of complications secondary to the use of microwave ablation (MWA) in non-small-cell lung cancer (NSCLC) are discussed herein. The first case involves a 62-year-old man with stage IB NSCLC who declined surgery and pursued MWA. Within 7 months, he had residual disease at the MWA treatment site, and surgery was...

journal_title：Clinical lung cancer

authors： Padda S,Kothary N,Donington J,Cannon W,Loo BW Jr,Kee S,Wakelee H

更新日期：2008-03-01 00:00:00

abstract：BACKGROUND:Elderly patients are underrepresented in trials that establish definitive chemoradiotherapy as the standard of care for inoperable stage III non-small-cell lung carcinoma (NSCLC). This study analyzed radiotherapy treatment delivery and outcomes at our institution according to elderly (≥ 70 years old) or youn...

journal_title：Clinical lung cancer

authors： Aridgides PD,Janik A,Bogart JA,Duffy S,Rosenbaum P,Gajra A

更新日期：2013-11-01 00:00:00

abstract：:Lung cancer remains the number one cause of cancer-based mortality in men and women. The importance of proper lung cancer care outside of major academic centers cannot be overemphasized because the vast majority of lung cancer care occurs in community hospital settings. We have had the opportunity to develop a highly ...

journal_title：Clinical lung cancer

authors： Fischel RJ,Dillman RO

更新日期：2009-07-01 00:00:00

abstract：:Implementation of positron-emission tomography (PET) is variable depending on jurisdiction in part due to uncertainty about cost-effectiveness. Our objective was to perform a systematic review describing cost-effectiveness of PET in staging of non-small-cell lung cancer (NSCLC) and management of solitary pulmonary nod...

journal_title：Clinical lung cancer

authors： Cao JQ,Rodrigues GB,Louie AV,Zaric GS

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...

journal_title：Clinical lung cancer

authors： Go SI,Keam B,Kim TM,Lee SH,Kim DW,Kim HJ,Wu HG,Chung DH,Heo DS

更新日期：2014-03-01 00:00:00

abstract：UNLABELLED:Extrapolation of clinical trials results to the general population is always challenging. We analysed 1047 patients diagnosed with an advanced stage disease between 1998 and 2005 in a french administrative department and found a good spread of modern chemotherapy since 1998 and targeted therapy since 2002. M...

journal_title：Clinical lung cancer

authors： Carpentier O,Selvaggi L,Jégu J,Purohit A,Prim N,Velten M,Quoix E

更新日期：2015-11-01 00:00:00

abstract：:After decades of platinum-based chemotherapy for advanced small-cell lung cancer, there has finally been a therapeutic advance. The combination of a platinum chemotherapy, etoposide, and an immune checkpoint inhibitor has yielded overall survival benefits in two successive phase 3 trials. Unfortunately, these trials o...

journal_title：Clinical lung cancer

authors： Friedlaender A,Liu SV,Passaro A,Metro G,Banna G,Addeo A

更新日期：2020-11-01 00:00:00

abstract：:The therapeutic options for patients with advanced non-small-cell lung cancer (NSCLC) are palliative. Therefore, the quality of life in oncology is considered as an endpoint in clinical trials, and several scales have been accepted for its measurement in parallel with other clinical determinations. However, its use in...

journal_title：Clinical lung cancer

authors： Camps C,del Pozo N,Blasco A,Blasco P,Sirera R

更新日期：2009-03-01 00:00:00

abstract：INTRODUCTION:The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without simultaneous integrated boost (SIB) on fluorodeoxyglucose-positron emission tomography (FDG-PET) positive areas (gross tumor volume [GTV]-PET) for patients ...

journal_title：Clinical lung cancer

authors： Fodor A,Broggi S,Incerti E,Dell'Oca I,Fiorino C,Samanes Gajate AM,Pasetti M,Cattaneo MG,Passoni P,Gianolli L,Calandrino R,Picchio M,Di Muzio N

更新日期：2019-01-01 00:00:00

abstract：:Conducting research in patients with non-small-cell lung cancer (NSCLC) is challenging, primarily because of low patient accrual rates resulting from patient-, physician-, protocol-, and healthcare system-related barriers. The Coalition of Cancer Cooperative Groups convened a 1-day program entitled Addressing the Curr...

journal_title：Clinical lung cancer

authors： Curran WJ Jr,Schiller JH,Wolkin AC,Comis RL,Scientific Leadership Council in Lung Cancer of the Coalition of Cancer Cooperative Groups.

更新日期：2008-07-01 00:00:00

abstract：BACKGROUND:ROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves survival in the approximately 1% to 2% of patients with lung adenocarcinoma with ROS1 gene fusions. Although fluorescence in situ hybridization (FISH) is the standa...

journal_title：Clinical lung cancer

authors： Boyle TA,Masago K,Ellison KE,Yatabe Y,Hirsch FR

更新日期：2015-03-01 00:00:00

abstract：:Novel therapies have been added to the treatment arsenal of physicians treating lung cancer in recent years. Most promising are agents that target the major pathways involved in cancer evolution, mostly proliferation and angiogenesis. Some of these treatments have been shown to synergize with traditional chemotherapy ...

journal_title：Clinical lung cancer

authors： Bar J,Herbst RS,Onn A

更新日期：2008-01-01 00:00:00

abstract：:The Lung Cancer Disease Site Group (DSG) of the Cancer Care Ontario Practice Guidelines Initiative first met in January of 1994. Included in the membership were three pathologists who, with the other members of the DSG, felt that a useful contribution to the work of the group would be a recommendation on standardized ...

journal_title：Clinical lung cancer

authors： Chamberlain DW,Wenckebach GF,Alexander F,Fraser RS,Kolin A,Newman T

更新日期：2000-05-01 00:00:00

abstract：INTRODUCTION:The effect of local therapy (LT) for oligoprogressive epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has not been well established. Forty-six patients with stage IIIB/IV EGFR-mutated NSCLC were treated by LT and continuing tyrosine kinase inhibitors (TKIs) for oligoprogr...

journal_title：Clinical lung cancer

authors： Qiu B,Liang Y,Li Q,Liu G,Wang F,Chen Z,Liu M,Zhao M,Liu H

更新日期：2017-11-01 00:00:00

abstract：:This phase I/II study was conducted to evaluate the safety and efficacy of tirapazamine in combination with cisplatin and vinorelbine for patients with advanced-stage IIIB/IV chemonaive non-small-cell lung cancer. Seventy patients with a Karnofsky performance status of > or = 60% were included. In the phase I part of ...

journal_title：Clinical lung cancer

authors： Gatineau M,Rixe O,Chevalier TL

更新日期：2005-03-01 00:00:00

abstract：:The combination of chemotherapy and radiation has been validated for the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the results are still unsatisfactory, and there is a need to improve current treatment. One approach is to use new agents that have the potential to enhance the efficacy o...

journal_title：Clinical lung cancer

authors： Edelman MJ

更新日期：2005-10-01 00:00:00

abstract：INTRODUCTION/BACKGROUND:The aim of this study was to identify imaging-based predictors of progression in patients treated with SABR for stage I NSCLC. PATIENTS AND METHODS:Between March 2003 and December 2012, 117 patients with stage I NSCLC meeting our study criteria were treated with SABR at Stanford University. Med...

journal_title：Clinical lung cancer

authors： Shultz DB,Trakul N,Abelson JA,Murphy JD,Maxim PG,Le QT,Loo BW Jr,Diehn M

更新日期：2014-07-01 00:00:00

abstract：BACKGROUND:In 2007, the European Organization for Research and Treatment of Cancer (EORTC) study (ClinicalTrials.gov identifier, NCT00016211) demonstrated a beneficial effect on overall survival (OS) with the use of prophylactic cranial irradiation (PCI) for extensive disease (ED) small-cell lung cancer (SCLC). Neverth...

journal_title：Clinical lung cancer

authors： Bernhardt D,Adeberg S,Bozorgmehr F,Opfermann N,Hoerner-Rieber J,Repka MC,Kappes J,Thomas M,Bischoff H,Herth F,Heußel CP,Debus J,Steins M,Rieken S

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:The immune checkpoint proteins programmed death-1/ligand (PD-1/PD-L1) play a critical role in immune escape of tumor cells. In models of epidermal growth factor receptor (EGFR)-driven non-small-cell lung cancer (NSCLC), EGFR signal upregulates PD-1/PD-L1. However, data on the clinical significance of PD1/PD-...

journal_title：Clinical lung cancer

authors： Lin C,Chen X,Li M,Liu J,Qi X,Yang W,Zhang H,Cai Z,Dai Y,Ouyang X

更新日期：2015-09-01 00:00:00

abstract：:Recent developments in the chemotherapy of advanced and metastatic non small-cell lung cancer have led to significant, albeit modest, improvements in survival and quality of life. The plethora of new agents with activity in this disease has led to questions as to how these drugs can best be added to existing regimens....

journal_title：Clinical lung cancer

authors： Edelman MJ,Gandara DR

更新日期：1999-11-01 00:00:00

abstract：BACKGROUND:The aim of this trial was to determine feasibility of incorporating bevacizumab (B) into concurrent chemoradiotherapy (CRT) for locally advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Patients with unresectable stage III NSCLC, performance status of 0 to 1, and adequate organ function were...

journal_title：Clinical lung cancer

authors： Wozniak AJ,Moon J,Thomas CR Jr,Kelly K,Mack PC,Gaspar LE,Raben D,Fitzgerald TJ,Pandya KJ,Gandara DR

更新日期：2015-09-01 00:00:00

abstract：:This study was designed as a multicenter, randomized, double-blind, placebo-controlled trial. Patients were randomized by center to placebo (16 patients, 31%), oral bexarotene 300 mg/m2/day (21 patients, 40%), or oral bexarotene 600 mg/m2/day (15 patients, 29%) following demonstration of stable or responsive disease a...

journal_title：Clinical lung cancer

authors： Rizvi N,Hawkins MJ,Eisenberg PD,Yocum RC,Reich SD,Ligand L1069-20 Working Group.

更新日期：2001-02-01 00:00:00

abstract：BACKGROUND:Y-box binding protein 1 (YB-1) is an oncogenic transcription factor that is activated in response to various genotoxic stresses. The purpose of this study was to elucidate whether YB-1 correlates with the expression of lung resistance-related protein (LRP) and epidermal growth factor receptor (EGFR) in prima...

journal_title：Clinical lung cancer

authors： Hyogotani A,Ito K,Yoshida K,Izumi H,Kohno K,Amano J

更新日期：2012-09-01 00:00:00

abstract：:Docetaxel has demonstrated activity as a radiosensitizer in numerous preclinical studies, probably due to its role as a cell cycle synchronizer for the G2/M radiosensitive phase of the cell cycle. We conducted a phase I trial to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLT) of docetaxel...

journal_title：Clinical lung cancer

authors： Choy H,DeVore RF,Hande KR,Porter LL,Rosenblatt PA,Slovis B,Laporte K,Shyr Y,Johnson DH

更新日期：2000-04-01 00:00:00

abstract：BACKGROUND:Hormesis is a favorable biological response to low toxin exposure. In the case of radiation, large doses are carcinogenic, but low doses might be protective. In the current study, we analyzed lung cancer incidence in high-impact radiation states where nuclear testing occurred and compared it with lung cancer...

journal_title：Clinical lung cancer

authors： Lehrer S,Rosenzweig KE

更新日期：2015-03-01 00:00:00

abstract：:The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving...

journal_title：Clinical lung cancer

authors： Pacheco J,Bunn PA

更新日期：2019-05-01 00:00:00

abstract：:Bevacizumab is the first molecularly targeted agent associated with improved outcomes in combination with chemotherapy in previously untreated patients with non-small-cell lung cancer (NSCLC). The addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to carboplatin and pacli...

journal_title：Clinical lung cancer

authors： Morgensztern D,Govindan R

更新日期：2008-03-01 00:00:00

abstract：:Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The associ...

journal_title：Clinical lung cancer

authors： Imbimbo M,Vitali M,Fabbri A,Ottaviano M,Pasello G,Petrini I,Palmieri G,Berardi R,Zucali P,Ganzinelli M,Marabese M,Broggini M,Marino M,Trama A,Rulli E,Hollander L,Pruneri G,Torri V,Garassino MC

更新日期：2018-09-01 00:00:00

abstract：INTRODUCTION:Clinical manifestation of non-small-cell lung cancer (NSCLC) mainly occurs at advanced stages. Thus, the scientific community is evaluating different screening programs in high-risk patients to detect NSCLC at an earlier stage to improve survival. However, up to now patient selection and modalities have be...

journal_title：Clinical lung cancer

authors： Kocher F,Lunger F,Seeber A,Amann A,Pircher A,Hilbe W,Fiegl M

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Real-world data on current treatment practices for non-small-cell lung cancer (NSCLC) are needed to understand the place in therapy and potential economic impact of newer therapies. PATIENTS AND METHODS:This retrospective cohort study identified patients ≥ 65 years old in the Surveillance, Epidemiology, a...

journal_title：Clinical lung cancer

authors： Arunachalam A,Li H,Bittoni MA,Camacho R,Cao X,Zhong Y,Lubiniecki GM,Carbone DP

更新日期：2018-09-01 00:00:00